URIT Medical’s Post

The last ISNCT newsletter is here! 📬 In this edition, we look forward to the ICNCT-20! Super excited to meet in person after so many years. Very important news arrived from Xiamen BNCT Center, with the start of clinical trials. You will also find new articles at our repository and a reminder of a call for papers for a special issue. 🚨 Major updates from Neuboron Medical Group: Medical Device Testing Success for the NeuPEX Block-I system. IND Approval for BPA, setting the stage for Phase-I clinical trials. Phase-I Trial at Xiamen Humanity Hospital starting April 2024. 📄 Explore new articles in our repository: Dosimetry Code of Practice for BNCT. The paradigm shift of BNCT in radiation oncology. 💻 Contribute to the special issue "Boron in Medicinal Chemistry: From Synthesis to Therapeutic Applications" in Pharmaceuticals journal. For more detailed information, visit our website through the Link in Bio. Don’t miss out on the latest advancements in BNCT! You can find all the newsletters on our website, in our Link in Bio. Want to subscribe to the newsletter? You can also do it on our website. #newsletter #BNCT #CancerTherapy #ICNCT20 #Neuboron #ISNCT #MedicalAdvancements

Spherix's Patient Chart Dynamix™ reveals AstraZeneca’s Saphnelo as having the highest use among CLE patients, surpassing its use in SLE or SLE/LN. Approved for SLE and in Phase 3 for CLE, Saphnelo is on track to potentially become the first therapy approved specifically for CLE. 🌟Other promising CLE treatments in the pipeline include Biogen’s litifilimab, Bristol Myers Squibb’ Sotyktu, Amgen’s daxdilimab, Merck’s enpatoran, and Gilead Sciences’s GS-5718. 𝗪𝗵𝗮𝘁 𝘄𝗼𝘂𝗹𝗱 𝘆𝗼𝘂 𝗱𝗼 𝘄𝗶𝘁𝗵 𝘂𝗻𝗽𝗮𝗿𝗮𝗹𝗹𝗲𝗹𝗲𝗱 𝗺𝗮𝗿𝗸𝗲𝘁 𝗲𝘅𝗽𝗲𝗿𝘁𝗶𝘀𝗲 𝗮𝗻𝗱 𝟰𝟬𝟬 𝗖𝗟𝗘 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗰𝗵𝗮𝗿𝘁𝘀 𝗮𝘁 𝘆𝗼𝘂𝗿 𝗱𝗶𝘀𝗽𝗼𝘀𝗮𝗹❓ #marketresearch #rheumatology #CLE #SLE

Get insights on how the EU's new In Vitro Diagnostic Regulation (IVDR) affects labs running in-house LC-MS/MS tests (LDTs). This webinar is for you if: ➡️You use LC-MS/MS for Laboratory Developed Tests (LDTs) ➡️You're unsure about the IVDR's impact on your lab Register here: https://lnkd.in/eWAjUwVb #IVDR #LCMSMS #LDTs #InVitroDiagnostics Tecan

Next stop on NEB's 50-stop world tour: 📍London! Excited to be exhibiting at Advanced Therapies 2024 next week. Stop by booth 21 to chat with NEB, learn more about our GMP capabilities and how we can support you at different stages of your ATMPs pipeline. @Marc Davis, @Chris Lounds, @Laura Wood, @Euan Forbes Ph.D #mRNA #RNA #Therapeutics #NEBturns50 #AdTherapies24 #CellTherapy #GeneTherapy"

Meet Matthew Peterfreund this week at #WorldADC and discuss how single-cell Interaction Cytometry can advance your #AntibodyDrugConjugate research project by providing unprecedented insights into the interaction of your conjugates with their targets directly on the surface of the target cells! #DiscoverMolecularInteractions #scIC

https://lnkd.in/eXJSG6sy We’re thrilled to announce that our investigational Acellular Tissue Engineered Vessel (ATEV™) has received the FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for advanced Peripheral Artery Disease (PAD) treatment. This marks our third RMAT designation, a testament to our commitment to innovation and patient care. Our previous RMAT designations were for vascular trauma repair and arteriovenous (AV) access in hemodialysis. What does this mean?  The RMAT designation has the potential to accelerate the development and review process, allowing us to work closely with the FDA and potentially an expedited/priority review of a Biologics License Application (BLA). Our ATEV is designed to be a universally implantable vascular conduit, offering a potential option for PAD patients who lack other treatment options.  Stay tuned as we continue to advance this exciting technology, with the goal of improving outcomes for PAD patients worldwide. #Humacyte #Innovation #Healthcare #Biotech #FDA #RMAT #PAD #VascularHealth

We couldn't be prouder of Lexitas senior leaders Andrew D. Pucker, OD, PhD, and Lanita Scott, M.D. for their contributions to this publication of the most comprehensive summary of ophthalmic clinical trial metrics in the US to date! These findings and insights will be invaluable to stakeholders across the industry, helping to drive more precise enrollment planning and ensure successful execution as we collectively work toward better outcomes. Follow the link to read the full report which includes: -Most studied indications -List of most prolific ophthalmic trial Sponsors -List of most studied drugs -Enrollment rates by indication and trial phase Read more here: https://lnkd.in/gTZ7f4Xb #clinicalresearch #ophthalmology #Lexitas #metrics #enrollment #thoughtleadership

🔬 Attention Healthcare Providers! Phase 2 Registration for DEX Z-Codes® Now Open Starting August 1, 2024, you can begin registering tests that fall within the scope of phase 2 of the DEX Z-Codes® for certain molecular diagnostic test services. As part of our recently updated Molecular Pathology Reimbursement Policy (Professional and Facility), which took effect on June 1, 2024, They are implementing this important requirement. 🔍 What’s New? Phase 2 Scope: Tests subject to phase 2open_in_new must include the appropriate Z-code on their claims. Effective Date: Claims with dates of service on or after November 1, 2024, will be considered for reimbursement if they comply with the Z-code requirement. Test Code Registration Phases: UHC send you timely reminders about each registration phase. You’ll receive notifications at least 30 days in advance of the start date. Phase 2 Registration: Get ahead by registering your tests starting August 01, 2024. 🔗 #HealthcareBilling #MolecularDiagnostics #ZCodes #Reimbursement Sonora Quest Laboratories/ Laboratory Sciences of Arizona Quest Diagnostics UHC Labcorp Palmetto GBA

Are you navigating the complexities of preclinical and clinical trials? Let’s make it simpler together! Meet us at #ASGCT24, booth 2172, where Accelevir and Noble Life Sciences unite to accelerate your path from discovery to delivery. Dive into our full-service offerings in drug, vaccine, and medical device development, enhanced by precise cell and biomarker analytics. 🧬💡 👋 Swing by for a chat, learn more about our exciting collaboration, and enter our iPad raffle! #baltimore #ASGCT24 #cellandgene

Let's meet at CDx in Boston to discuss how NeoGenomics can support your end to end strategy with biomarker and genomics data from over 1M patients tested annually at NeoGenomics! #oncologydata #OncologyRWD